Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

(2018) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis

(2018) Zhenling Yao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

(2018) Yan Xu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

(2018) Jason Reinglas et al.   WORLD JOURNAL OF GASTROENTEROLOGY

A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD

(2018) Kenechukwu O Chudy-Onwugaje et al.   INFLAMMATORY BOWEL DISEASES

Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease

(2017) Chuanpu Hu et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

(2015) M. Rosario et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Optimizing the use of biological therapy in patients with inflammatory bowel disease

(2015) A. C. Moss   Gastroenterology Report

Ustekinumab: A Review of Its Use in Psoriatic Arthritis

(2014) Kate McKeage   DRUGS

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

(2014) Chuanpu Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

(2012) I Ordás et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis

(2011) Y.W. Zhu et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

(2009) Honghui Zhou et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Confirmatory analysis for phase III population pharmacokinetics

(2009) Chuanpu Hu et al.   PHARMACEUTICAL STATISTICS

An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

(2008) Chuanpu Hu et al.   JOURNAL OF CLINICAL PHARMACOLOGY